Diligence memo · auto-generated · as of July 2, 2026
BioVaxys Technology Corp.
BioVaxys Technology Corp. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
BioVaxys Technology Corp. operates in Biotechnology, based in VANCOUVER.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BioVaxys Technology Corp. has raised $249K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $249K on 2021-07-14.
Most recent recorded round closed around 2021-07-14.
Valuation (modeled)modeled
Provath models BioVaxys Technology Corp. at approximately $7.2M (range $133K–$60M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.46× the median modeled value of Pre-Seed Biotechnology companies in 2019–2021 (156 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 5.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 5% of Biotechnology peers (4293 compared).
Modeled value ranks above 14% of those peers.
Closest niche peers: Crimson BioPharm Inc., Pinpoint Therapeutics Inc., Transplant Logistics & Informatics Llc, RNAissance AG LLC, Pylum Biosciences, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.